Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Olumiant ® (baricitinib)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Can I give Olumiant® (baricitinib) and oral contraceptives concomitantly in patients with rheumatoid arthritis?
The concomitant use of baricitinib and oral contraceptives is not contraindicated. In rheumatoid arthritis clinical trials, some patients treated with baricitinib were taking concomitant oral contraceptives.
UK_cFAQ_BAR305A_CONCOMITANT_ORAL_CONTRACEPTIVES_RA
en-GB
Clinical trial exclusion criteria
Women of childbearing potential were excluded from the study if they did not agree to use 2 forms of highly effective birth control when having sex during the study and for at least 28 days after the last dose.1
Pharmacokinetics considerations
Based on clinical pharmacology studies, baricitinib (BARI) had no effect on the pharmacokinetics of the components of the combined oral contraceptive Microgynon® (Bayer, United Kingdom), a cytochrome (CYP) 3A substrate.2
No clinically relevant effects on BARI pharmacokinetics occurred with the co-administration of BARI and
- a CYP 3A inhibitor
- a CYP2C19/CYP2C9/CYP 3A inhibitor
- a CYP 3A inducer, or
- a P-glycoprotein (Pgp) inhibitor.2
Safety considerations based on the use of oral contraceptives and association of venous thromboembolism
In all BARI-treated patients with RA, risk factors possibly associated with venous thromboembolism (VTE) events were evaluated in a single- and multi-variable analysis comparing the risks between patients with (n=42) and without events (n=3450) using data through April 1, 2017.3
Concomitant use of BARI and oral contraceptive pills or selective estrogen receptor modulators was observed in
- 3 (7.1%) of the 42 patients with VTE, and
- 214 (6.2%) of the 3450 patients without VTE.1
No association was observed between concomitant use of oral contraceptive pills or selective estrogen receptor modulators and incidence of VTE.1
Safety considerations based on the SmPC
Deep venous thrombosis (DVT) and pulmonary embolism (PE) are listed as uncommon in the table of adverse reactions in the summary of product characteristics. 4
Baricitinib should be used with caution in patients with risk factors for DVT/PE, such as
- older age
- obesity
- a medical history of DVT/PE, or
- patients undergoing surgery and immobilisation.4
If clinical features of DVT/PE occur,
- discontinue baricitinib
- evaluate your patient promptly, and
- treat it appropriately.4
References
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Payne C, Zhang X, Shahri N, et al. Evaluation of potential drug-drug interactions with baricitinib. Ann Rheum Dis. 2015;74(suppl 2):1063. European League Against Rheumatism abstract AB0492. http://dx.doi.org/10.1136/annrheumdis-2015-eular.1627
3Eli Lilly and Company. Lilly FDA Advisory Committee Meeting NDA 207924 Briefing Document. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM605062.pdf. Accessed July 23, 2018. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM605062.pdf
4Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Date of Last Review: 11 March 2021
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays